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Abstract
Peripheral nerve injury remains a major cause of morbidity in trauma patients. Despite
advances in microsurgical techniques and improved understanding of nerve regeneration,
obtaining satisfactory outcomes after peripheral nerve injury remains a difficult clinical
problem. There is a growing body of evidence in preclinical animal studies demonstrating
the supportive role of stem cells in peripheral nerve regeneration after injury. The charac-
teristics of both mesoderm-derived and ectoderm-derived stem cell types and their role in
peripheral nerve regeneration are discussed, specifically focusing on the presentation of
both foundational laboratory studies and translational applications. The current state of
clinical translation is presented, with an emphasis on both ethical considerations of using
stems cells in humans and current governmental regulatory policies. Current advance-
ments in cell-based therapies represent a promising future with regard to supporting nerve
regeneration and achieving significant functional recovery after debilitating nerve injuries.
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1 | INTRODUCTION
Peripheral nerve injury remains a major cause of morbidity in trauma
patients.1 Despite advances in microsurgical techniques and improved
understanding of nerve regeneration, obtaining satisfactory outcomes
after peripheral nerve injury remains a serious clinical problem.2-4
Unfortunately, a large proportion of patients with severe peripheral
nerve injuries fail to recover normal function.5,6 Even after the most
optimal surgical situation of direct nerve repair, return of motor and
sensory function is slow and often incomplete.7-9
The regeneration of damaged peripheral nerves occurs though a
complex process in which Schwann cells (SCs) play a crucial role.10 After
axonal injury, SCs proliferate, phagocytose debris, and recruit macro-
phages11 to help establish the optimal regenerative milieu.12 These cells
further aid in axonal regrowth by synthesizing neurotrophic factors,13-15
producing both extracellular matrix and cell-adhesion molecules,16 and
providing physical guidance to regenerating axons.17,18 SC-based thera-
pies have been successfully utilized in preclinical animal models to
enhance nerve regeneration.19-22 However, due to the invasive nature
of SC harvest23 and the difficulty of cell expansion in vitro,24 there remain
significant barriers to clinical use.25
In light of the practical limitations associated with SCs, there has
been growing enthusiasm for the use of both precursor and stem cell–
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based therapies (we use the term “stem cell” throughout this review
to maintain consistency while recognizing that few of the cell sources
mentioned are true stem cells) for peripheral nerve regeneration.26-29
We are also cognizant of the fact that embryonic stem cells generally
have a higher regenerative capacity and are less lineage committed
than adult precursor and/or stem cells.30,31 There is a growing body
of evidence in preclinical animal studies showing that stem cells play a
positive role in the regeneration of peripheral nerves after injury.32-37
These effects are thought to be based on the ability of transplanted
stem cells to promote regeneration by cell differentiation into tissue-
specific cell types,38-40 signaling through cell-to-cell contact, and/or
sustained release of neurotrophic factors.27,41,42 A number of stem
cell types with varying phenotypic and gene expression profiles have
been investigated. In this review we summarize the literature
supporting the utilization of various stem cell types that have been
employed to enhance peripheral nerve regeneration. A detailed list of
the stem cell types discussed is presented in Table 1. We review the
foundational laboratory studies for each type and then focus on trans-
lational works using human-derived cells in animals. If available, the
current use of these cells in humans for the treatment of peripheral
nerve conditions is also highlighted.
2 | BONE MARROW STROMAL STEM
CELLS
One of the most comprehensively studied cell types with respect to
peripheral nerve regenerative potential is the bone marrow stromal
stem cell (BMSC). These multipotent cells may differentiate into mes-
enchymal lineages but can also be persuaded to adopt an SC pheno-
type in vitro.26 However, their eventual fate in vivo may not robustly
retain this differentiation.43,44
BMSCs effectively produce and secrete numerous neurotrophins
(eg, nerve growth factor [NGF], brain-derived neurotrophic factor
[BDNF], glial-cell-line–derived neurotrophic factor [GDNF], ciliary
neurotrophic factor [CNTF]) in peripheral nerve repair and have been
previously shown to enhance regeneration.45,46 Chen et al convinc-
ingly showed improved walking track scores, wet muscle weights, and
increased axonal counts in a 15-mm-gap sciatic transection model45
using BMSC therapy. These cells have also been tested (and found
efficacious) as supplements to nerve scaffolds using inside-out arterial
grafts,47 decellularized nerve grafts,48-51 and veins.52 One study
showed a relative inferiority of BMSCs when directly compared with
SCs for electrophysiological recovery of a sciatic transection/silicone
tube model, although functionally the groups performed at equivalent
levels.53 BMSCs have also been studied in larger animal models of
long-gap nerve regeneration, including rabbits54 and nonhuman
primates,55 and in the latter demonstrated efficacy on par with both
SCs and allografts.
A further notable observation is the ability of BMSCs to “home
in” to injured targets, where they have demonstrated this ability in
central nervous system animal injury models when administered
intravenously.56 Although BMSCs are yet to be used in humans, the
practicality of an effective systemic stem cell therapy makes these
cells a prime candidate for translational study.
3 | ADIPOSE-DERIVED STEM CELLS
Originally described by Zuk et al, adipose-derived stem cells (ADSCs)
present a potential adjunct to improve nerve repair and are derived
from adipose tissue, which in turn is derived from embryonic meso-
derm.57,58 However, they can be effectively differentiated along ecto-
dermal lines, with SC-like ADSCs, first described in 2007 by Kingham
and colleagues.38 Numerous studies have focused on neu-
roregenerative effects of adipose tissue using purified, cultured, dif-
ferentiated, or dedifferentiated adipose-derived tissues.59-61 ADSCs
have also been extensively investigated for use in peripheral nerve
regeneration, with promising results. They produce mRNA for the
growth factors BDNF, glial-growth–like factor (GGF), neurogulin-1
(NRG-1), vascular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF), and insulin-like growth factor (IGF) on par or
greater than SCs in culture.41 ADSCs support a robust neurite
response38 and myelinate dorsal root ganglion (DRG) neurites
in vitro.62 When used in animal models, they may be superior to both
SCs and mesenchymal cells for regeneration through a fibrin con-
duit.63 They have also demonstrated efficacy in improving recovery in
both acute and chronic sciatic denervation injury paradigms in
rodents.62,64
One benefit of ADSCs for clinical translation is the relative abun-
dance of adipose tissue for harvest. In this regard, human adipose-
derived mesenchymal cells obtained from abdominal fat was shown to
improve recovery metrics when injected into a murine sciatic crush
model, as demonstrated by sciatic functional index (SFI) and walking
track analysis. Remarkably, in the study, these cells were injected sys-
temically (intravenously) and were found to localize at the area of
injury.65 As a counterpoint, it would seem that mesenchymal cells
derived from human adipose tissue may not maintain their SC-like
phenotype for long when withdrawn from the permissive in-vitro
cocktail of mitogens and growth factors, as recently demonstrated by
Faroni et al.66 Adult adipose mesenchymal cells also have known limi-
tations in terms of senescence and donor-age–dependent efficacy,
making their specific clinical indications the subject of future research.
4 | AMNIOTIC MESENCHYMAL STROMAL
CELLS
Amniotic mesenchymal stromal cells (AMSCs) are derived from the avas-
cular amniotic mesoderm, and are relatively non-immunogenic cells.67-70
Because of this, their membrane has been investigated as a cellular scaf-
fold both in vivo71 and ex vivo.67 Recently, the in-toto amniotic membrane
has been differentiated toward an SC phenotype and proposed as a scaf-
fold alternative to autograft repair.72 AMSCs have been compared with
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ADSCs in a sciatic nerve crush model, and were found to be better at
improving electrophysiological and functional recovery at 4 weeks post-
injury.73 Interestingly, the AMSCs markedly improved the overall perfu-
sion vascularity of the injured sciatic nerve distal to the crush (Figure 1),
in keeping with their known angiogenic profile.74
AMSCs are an interesting candidate for human transplantation
experiments, with their demonstrated ability to graft effectively into
non-autologous environments.75,76 Such biocompatibility may enable
allograft cell banks to be developed for immediate human use, without
the need for posttransplant immunosuppression.
5 | UMBILICAL CORD MESENCHYMAL
CELLS
The umbilical cord is a valuable source for mesenchymal stem cells,
both from the Wharton jelly77,78 and umbilical cord blood.79-83 These
are multipotent cells that are likely of two distinct populations: one
with a propensity to differentiate into neuronal ectodermal pheno-
types, and another with a mesodermal lineage production.79 These
cells have been previously shown to express pluripotent stem cell
markers, such as Oct4, Nanog, Sox2, ABCG2, and the neu-
roectodermal marker nestin.79 There are several potential advantages
to the use of these cells, including: 1) ease of accessibility; 2) the fact
that they are immunologically inert; 3) their use bears no ethical
considerations; and 4) they possess a low probability of resulting in
graft-vs-host disease.83,84
As peripheral nerve regeneration support cells, the therapeutic
potential of human umbilical cord blood–derived stem cells
(hUCBDSCs) has been investigated in studies of cavernous nerve
injury, recurrent laryngeal nerve injury, optic nerve injury, and sciatic
nerve injury,85-89 all with varying degrees of success. hUCBDSCs were
shown to improve recovery from rat sciatic nerve crush injury, with
improved SFI over noninjured controls as well as increased expression
of both BDNF and tyrosine kinase B (TrkB) receptor mRNA. Wharton
jelly–derived umbilical mesenchymal cells also seem to improve recov-
ery from rodent sciatic nerve crush, showing improvements in SFI,
myelin histology, and sensory hindlimb function.78
6 | DENTAL PULP STEM CELLS
Thought to be an embryological derivative of the cranial neural
crest,39,90 human dental pulp houses a progenitor mesenchymal popu-
lation that easily differentiates into both a neural and SC phenotype
in vitro.91-93 First described by Gronthos and colleagues in 2000,
DPSCs are self-renewing, and express numerous stem cell markers
such as CD29, CD90, CD271, nestin, and glial fibrillary acidic protein
(GFAP), and do not express hematopoietic markers.94-97 These cells
have been shown to be able to differentiate into numerous tissue
types, including neurons,98 myoctes,99 hair follicle cells,100 and hepa-
tocytes.101 However, research has also shown that these cells are sus-
ceptible to cellular senescence, and that they secrete toxic factors to
adjacent tissues when they develop this phenotype.102
DPSCs were used in experimental models of optic nerve injury,
where they have been shown to promote neurotrophin mediated reti-
nal ganglion cell (RGC) survival, and axonal regeneration after optic
nerve injury.103 When cocultured in vitro with DRG cells, DPSCs
displayed increased survival, neuritogenesis, and myelination when
compared with undifferentiated DPSC cultures.92,104 These cells also
demonstrated myelinating capacity and improved functional recovery
from rodent sciatic nerve transection.105 They have been shown to
counterbalance peripheral nerve injury–induced oxidative stress and
neuroinflammation.106 Interestingly, these cells may have their regen-
erative effects seen in crush injury enhanced by application of an
external pulsed electromagnetic field.107 Clinically, wisdom teeth may
one day be a potential source of autologous donation for this particular
type of stem cell for use in the treatment of peripheral nerve injuries.
7 | SKELETAL MUSCLE–DERIVED STEM
CELLS
Isolated skeletal muscle–derived stem cells (Sk-SCs) obtained from
skeletal muscle satellite cells are able to differentiate into multiple lin-
eages, including myogenic, adipogenic, osteoblastic, neuronal, and
glial.42,108-110 These cells therefore display a clonal productivity some-
where on the spectrum between ectodermal and mesodemeral.111
F IGURE 1 Transplantation of AMMs augments blood
perfusion. A, Representative images of blood perfusion in the sciatic
nerve. Blood perfusion was performed 4 weeks after the initial
operation with LDPI (Moor Instrument, Wilmington, Delaware). B,
Quantitative analysis using LDPI. AMMs significantly improved blood
perfusion compared with ADM stem cells and PBS. LDPI of blood was
done 4 weeks after the operation, as described elsewhere.14 Briefly,
the mice were anesthetized and placed on a heating blanket to
maintain a constant temperature. The nerves were exposed by using
blunt dissection and scalpel incision. The blood flow in the sciatic
nerve was examined using LDPI. ADM, adipose-derived
mesenchymal; AMM, amniotic membrane–derived mesenchymal stem
cell; LDPI, laser Doppler perfusion imaging; PBS, phosphate-buffered
saline. **P < .01; *P < .05 (n = 9 per group). Source: Data excerpted
from Li et al (2014).73
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In a murine model of a long nerve gap injury using an acellular scaf-
fold, Sk-SC–seeded grafts demonstrated improved histomorphological
metrics of recovery vs control grafts. These cells formed SCs as well as
cells of both the endo- and perineurial architecture, suggesting that Sk-
SCs may help in forming coordinated regeneration by being able to
reconstitute the muscle-nerve-blood vessel unit.112 Interestingly, the
F IGURE 2 Differentiated NCCs show enhanced in-vivo sciatic nerve regeneration. A-P, Immunohistochemical and histological analyses of
longitudinal sections through transplanted biodegradable conduits seeded with control rat Schwann cells (a-d), hESCs (e-h), or differentiated
NCCs (i-p). Dashed lines mark the walls of the conduits. Asterisks represent the site of nerve transection and the beginning of the regeneration
front. Q, Axon profile numbers beginning 1 mm distal to the proximal stump. The data represent the mean ± standard deviation of five
independent measurements from each animal and condition. Scale bars: 500 μm for a, e, i, and m; 200 μm for b, c, f, j, g, k, and n; 50 μm for d, h,
and l; and 20 μm for o and p. hESCs, human embryonic stem cells; HNA, human nuclear antigen; NCC, neural crest cell; SC, Schwann cells.
P values are denoted as follows: ns = not significant; **P ≤ .01; ***P ≤ .001; ****P ≤ .0001. Source: Data adapted from Jones et al (2018).138
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same research group also used human-derived Sk-SCs in a murine sciatic
graft model with similar positive results in both histological parameters
as well as metrics of tibial muscle health.113
8 | OLFACTORY ENSHEATHING CELLS
This cell class originates as the myelinating cell of the olfactory bulb in
fetal development.114 Olfactory ensheathing cells (OECs) have dem-
onstrated an ability to respond to injury by secretion of an extensive
array of neurotrophins,115 and also act as the primary phagocytic cell
of the olfactory bulb,116 clearing debris and bacteria alike.117
OECs have shown great promise in restoring function and improving
histological injury parameters in animal models of spinal cord
injury,118-122 and they remain one of the few cell types to be utilized
experimentally in clinical human spinal cord injury.123,124 However, their
utility in peripheral nerve injury remains less clear; although they inte-
grate and may improve function after rat sciatic nerve injury,125 their
efficacy in doing so may not be on par with transplanted SCs.126
9 | HAIR FOLLICLE–ASSOCIATED
PLURIPOTENT CELLS
Hair follicle–associated pluripotent (HAP) cells are nestin-expressing
cells that reside in the hair follicle and are thought to be intimately
involved in the formation of the hair follicle sensory nerve.127 They
are pluripotent and can differentiate into cells of both glial and neuro-
nal lineage,128 as well as smooth muscle myocytes, keratinocytes, and
melanocytes.129-131 One challenge is that HAP cells remain pluripo-
tent in regenerative models, transforming into both neurons and glia
in vivo.132 This presents a significant problem for the translatable util-
ity of these cells clinically. It is speculated that the skin-derived pre-
cursor (SKP) cell may be one of the early fates of the HAP cell.133
Newly regenerated axons from explanted hair follicles are highly
enriched in HAP cells in vitro, with their primary in-vivo function
thought to be the caretaking of the hair follicle sensory nerve.127 One
study showed that HAP cells appear to incorporate into the reg-
enerating microenvironment of a sciatic nerve transection injury,
although robust quantitative evidence of improved regeneration was
not present.134 Further investigation into seeding HAP cells in poly-
vinylidene fluoride membranes for a sciatic gap injury also demon-
strated good incorporation at the injury site. However, there was no
additional evidence of functional benefit according to walking track
analysis when compared with controls.132
10 | NEURAL CREST STEM CELLS
Neural crest stem cells (NCCs) originate in embryological development as
migratory progenitors that initially appear between the neural and sur-
face ectoderm at approximately embryologic day 8.112,135 These cells
maintain their multipotency during and after migration.136 NCCs have
been identified in both embryonic and postnatal adult tissues, including
bone marrow, DRG, carotid body, cornea, gut, heart, sciatic nerve, and
skin.137 NCCs are a promising strategic intervention for nerve repair
given that they are the parent population to several peripheral nervous
system lineages, including immature SC-like cells.138
NCCs that were differentiated from human embryonic–derived
support cells (hESCs) were shown to incorporate well into a murine
model of sciatic nerve repair and convincingly demonstrate histologi-
cal benefit over nontreated nerves, with more robust nerve diameter
and myelination demonstrated in cell treatment groups.139 Interest-
ingly, medium from differentiated NSCs enhanced outgrowth of DRG
neurites in vitro, while at the same time convincingly demonstrated
improved regeneration of NCC/scaffold-assisted sciatic nerve repair
on par with an SC-assisted cohort (Figure 2).138 Of note, these cells
were derived from hESCs, suggesting their efficacy in rodent models
of peripheral nerve regeneration.
11 | SKIN-DERIVED PRECURSOR CELLS
First isolated and characterized by Toma et al,140 skin-derived precursor
cells (SKPs) originate in dermal papilla and readily differentiate into
F IGURE 3 Lentiviral enhanced BFP SCs injected into Thy-1 GFP
rats that underwent doxorubicin-induced focal demyelination of the
tibial nerve. High-magnification intravital images of BFP-positive SKP-
SC myelination is shown, including a three-channel unmixed spectral
image demonstrating live in-vivo myelination by SKP-SCs 27 days
after doxorubicin tibial nerve injury, 19 days after cell injection. A,
GFP axons. B, Nile red myelin. C, BFP Schwann cells. D, Merged
image, where the arrow indicates a probable node of Ranvier, as
evidenced by BFP-positive cytoplasm crossing the axon, likely in
loosely packed paranodal myelin. BFP, blue fluorescent protein; SC,
Schwann cells; SKP-SC, skin-derived precursor Schwann cell. Source:
Data adapted from Grochmal et al (2018).144
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neurons and glia, as well as smooth muscle cells.40 Early work demon-
strated the efficacy of the SKP in assuming an SC lineage (SKP-SC) when
exposed to the proper mitogens,40 and extensive work followed to
investigate the role of the SKP-SC in peripheral nerve repair.27,141-143
SKP-SCs have proven beneficial in sciatic nerve repair with acellular
nerve grafts,142 and a delayed cross-reinnervation paradigm also demon-
strated an ability to improve regeneration after chronic denervation.27
We have previously injected lentiviral enhanced blue fluorescent protein
(BFP) SCs into Thy-1 green fluorescent protein (GFP) rats that underwent
doxorubicin-induced focal myelination.144 Our group showed that these
cells may aid regeneration through growth factor production,27 debris
clearance,145 and myelination144,146,147 (Figure 3).
In one experiment, SKP-SCs were impressively shown to improve
behavioral recovery, even after acute transection repair.145 Skilled loco-
motor assessments such as ladder rung and tapered beam were seen to
be improved in animals administered SKP-SCs after acute, chronic, and
nerve graft repair.145 In addition, it was recently shown that SKP-SC
action may in part involve their local immunomodulatory effect on both
neurites and macrophages, which appears to be mediated by an
interleukin-6–dependent mechanism.148 As a cell for translational ther-
apy, SKP-SCs seem quite promising. Human SKP-SCs are able to be pro-
duced by differentiation of human-induced pluripotent stem cells,149
whereas the practical expansion of clinically relevant numbers of SKP-
SCs has been shown to be possible through the use of bioreactors.143
12 | CURRENT STATE OF CLINICAL
TRANSLATION
In recent years we have seen tremendous progress in precursor and
stem cell biology and its application in the treatment of various neuro-
logical disorders. Clinical trials in the United States have evaluated the
regenerative benefits of stem cells in the context of multiple sclerosis
(MS), amyotrophic lateral sclerosis (ALS), Alzheimer disease (AD),
Duchenne muscular dystrophy (DMD), traumatic spinal cord injury,
and other disorders of the nervous system.35,124,150 Unfortunately,
there have been very few clinical trials examining the use of stem cells
in the clinical treatment of peripheral nerve pathologies,151 and none
specifically investigating the neuroregenerative benefits of stem cells
after traumatic peripheral nerve injury.35
Although the neuroprotective and regenerative potential of stem
cells in the repair of peripheral nerves has been demonstrated both
in vitro and in vivo in a number of animal models, it is currently unclear
when widespread clinical implementation of stem cell therapies will
become a reality. Of note, no cell-based approach has shown clear
superiority over another, and few preclinical studies have attempted
to compare one cell type with another.152 The literature is also limited
by the lack of data on the clinical safety and efficacy of stem cell–
derived therapies, with no long-term reports currently available. The
clinical use and early promise of autologous SC therapies in clinical
nerve repair153,154 suggest that cell types that can be readily pre-
differentiated in vitro to SCs (such as SKPs) or demonstrate
transdifferentiation to SCs in vivo (such as BMSCs and ADSCs) may
have the highest potential for clinical success. Levi and colleagues
from the University of Miami recently detailed the first-in-human use
of autologous SCs to supplement sciatic nerve repair.153,154 In these
groundbreaking studies, two patients were enrolled in a US Food and
Drug Administration–approved trial to assess both the safety and abil-
ity of autologous cultured SCs to enhance regeneration through sural
nerve autografts. Long-term follow-up in both patients demonstrated
nerve graft patency, absence of tumor formation, and significant
improvements in both sensory and motor impairments compared with
preoperative values.154
Although these initial clinical studies are encouraging, more rigor-
ous studies examining stem cell stability, differentiation, and migration
patterns are required before clinical safety is definitively
established.155 Metrics that accurately characterize the clinical effi-
cacy of stem cell–based therapies must also be identified. Current
peripheral nerve stem cell literature exhibits wide variability in animal
models, nerve injury type, stem cell source, differentiation protocols,
cell-delivery methods, and assessment of nerve regeneration. In par-
ticular, variations in the timing of diverse outcome measures between
different stem cell treatment modalities make specific treatments dif-
ficult to assess.35,37 These inconsistencies make it extremely difficult
to establish clear conclusions about efficacy or safety in a clinical
population. In addition, ethical considerations are a necessity when
translating research from the bench to bedside. Furthermore, govern-
mental restrictions and regulations may negatively affect the speed of
translation of stem cell therapy into clinical practice.156-158 Strategies
to manipulate cells using genetic and viral transduction approaches
in vitro to potentially enhance their effect in vivo (as recently
reviewed159) raise additional regulatory considerations. Nevertheless,
the evidence presented in this review suggests an promising future
for stem cell–based approaches to traumatic peripheral nerve damage,
although continued high-quality research is essential for bench-to-
bedside translation. Our opinion is that approaches that use stem and
precursor cells akin to an SC phenotype have the greatest potential
for clinical translation.
13 | CONCLUSION
Peripheral nerve injuries remain a common problem with unsatisfac-
tory functional outcomes after standard therapeutic interventions.
Several stem cell–based therapies have been investigated in both in-
vitro and in-vivo experiments to positively modulate the regenerative
milieu after nerve injury. These advancements suggest a promising
future for stem cell–based approaches in enhancing regeneration and
functional recovery after nerve injury.
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